OncoSec Medical Incorporated (ONCS)
| Market Cap | 6.72M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -29.39M |
| Shares Out | 2.97M |
| EPS (ttm) | -15.28 |
| PE Ratio | n/a |
| Forward PE | 8.67 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 936,717 |
| Open | 1.94 |
| Previous Close | 2.64 |
| Day's Range | 1.78 - 2.29 |
| 52-Week Range | 0.74 - 31.68 |
| Beta | 1.77 |
| Analysts | Sell |
| Price Target | 5.10 (+125.66%) |
| Earnings Date | Mar 14, 2023 |
About ONCS
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in clinica... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for ONCS stock is "Sell." The 12-month stock price forecast is $5.1, which is an increase of 125.66% from the latest price.
News
Why is OncoSec Medical (ONCS) Stock Up 91% Today?
OncoSec Medical (NASDAQ: ONCS) stock is rising higher on Wednesday after the company withdrew a public stock offering. According to the company, it no longer wants to move forward with the offering.
Why Is OncoSec Medical (ONCS) Stock Down 25% Today?
OncoSec Medical (NASDAQ: ONCS) stock is falling on Thursday after the company revealed details of a stock offering. The biggest news from the company's prospectus is warrants of its stock having an e...
Top 5 most-shorted stocks as of December 2022
More investors are interested in shorting and learning how they might benefit from a short squeeze as a result of the Reddit-fueled short squeeze on stocks like GameStop (NYSE: GME) and AMC Theaters (...
OncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022
PENNINGTON, N.J. and SAN DIEGO , Dec. 5, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing int...
OncoSec Announces Pricing of $3.5 Million Public Offering
PENNINGTON, N.J. and SAN DIEGO , Nov. 30, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing in...
ONCS Stock Alert: What to Know About OncoSec Medical as It Drops Today
Low-float stocks can do strange and unexpected things sometimes. That's as valid an explanation as any for the unusual price movement in OncoSec Medical (NASDAQ: ONCS) stock today.
OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma
PENNINGTON, N.J. and SAN DIEGO , Nov. 15, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical stage biotechnology company developing intratumoral ...
OncoSec Announces Positive Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment
PENNINGTON, N.J. and SAN DIEGO , Nov. 11, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral ...
OncoSec Announces Reverse Stock Split
PENNINGTON, N.J. and SAN DIEGO , Nov. 8, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing int...
OncoSec Announces Pipeline Prioritization and Workforce Reduction
PENNINGTON, N.J. and SAN DIEGO , Oct. 4, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing int...
Novel pre-clinical results regarding OncoSec's intratumoral electroporation platform were highlighted as Editor's Pick in Molecular Cancer Research
Results demonstrate novel synergistic effects of IL-12 and T cell receptor signaling in anti-tumor immunity PENNINGTON, N.J. and SAN DIEGO , June 24, 2022 /PRNewswire/ -- OncoSec Medical Incorporated ...
OncoSec Receives Triple Negative Breast Cancer Foundation's Vanguard Award for Excellence in Oncology Research
PENNINGTON, N.J. and SAN DIEGO , May 23, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec") today announced that it is the recipient of the 2022 Vanguard Awa...
OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer
PENNINGTON, N.J. and SAN DIEGO , April 29, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing i...
OncoSec Announces Appointment of George Chi as Chief Financial Officer
PENNINGTON, N.J. and SAN DIEGO, Feb. 22, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing int...
OncoSec Announces Changes to its Board of Directors
PENNINGTON, N.J. and SAN DIEGO, Dec. 17, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing cyt...
OncoSec Medical Hosting SITC Key Opinion Leader Webinar on Updated Data from the KEYNOTE-695 Study
PENNINGTON, N.J. and SAN DIEGO, Nov. 2, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) will host a conference call and webcast for investors and analysts on Friday, November 12 at 7:...
OncoSec Provides Business Update
PENNINGTON, N.J. and SAN DIEGO, Oct. 20, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing cyt...
OncoSec Provides Leadership Update
PENNINGTON, N.J. and SAN DIEGO, Aug. 16, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the establishment of a Leadership Committee consis...
OncoSec to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference
PENNINGTON, N.J. and SAN DIEGO, July 26, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that Interim CEO and Chief Operating Officer, Bria...
Why Shares Of OncoSec Medical Are Trading Higher Today
OncoSec Medical (NASDAQ: ONCS) shares are trading higher after the company announced it entered into a Clinical Trial Collaboration and Supply Agreement with Merck to evaluate the combination of OncoS...
OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO™ Combined with KEYTRUDA® for Late-Stage Metastatic Melanoma
PENNINGTON, N.J. and SAN DIEGO, July 6, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced it has entered into a Clinical Trial Collaboration ...
OncoSec Appoints Brian Leuthner as Interim Chief Executive Officer
PENNINGTON, N.J. and SAN DIEGO, June 24, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that Daniel O'Connor has resigned and that Brian L...
OncoSec Appoints Industry Leading Electroporation Device Expert, Jeffrey Silverman, as Vice President of Product Engineering
PENNINGTON, N.J. and SAN DIEGO, June 14, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), today announced the appointment of Jeffrey Silverman as Vice Pres...
OncoSec to Present at the Raymond James Human Health Innovation Conference
PENNINGTON, N.J. and SAN DIEGO, May 27, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that management will present a company overview at ...
OncoSec Appoints Robert M. Schinagl, Ph.D.
PENNINGTON, N.J. and SAN DIEGO, May 17, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the appointment of Robert M.